Please login to the form below

Not currently logged in

Good results for bipolar drug

Patients suffering from bipolar disorder could soon benefit from a new drug, Seroquel XL, which has shown positive performance during clinical trials
Patients suffering from bipolar disorder could soon benefit from a new drug, Seroquel XL, which has shown positive performance during clinical trials.

Manufactured by AstraZeneca and originally released in 1997, Seroquel (quetiapine fumarate) has already been approved for the treatment of schizophrenia in 88 countries, bipolar mania in 77 countries and bipolar depression in 11 countries including the US. It is hoped that the drug will receive approval for use in the UK as therapy for bipolar depression and mania.

Patients involved in the double-blind, placebo-controlled studies experienced significant reduction in their symptoms during he first week of treatment that lasted the course of both trials.

Results of two studies conducted to test the efficacy of the candidate drug, which is a once-daily monotherapy, were presented at the 8th International Review of Bipolar Disorder (IRBD).

Professor Patricia Suppes of Southwestern Medical School in Houston, Texas, said: "Quetiapine XL provided a reduction in symptoms for patients with bipolar disorder across mixed, manic and depressive episodes. That is encouraging for patients and physicians alike as a single medication that, if approved, can address the spectrum of mood episodes in bipolar disorder as a once-daily monotherapy is an attractive idea."

14th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....